News & Videos - CNS PHARMACEUTICALS INC. - English

You are currently viewing all stock exchange news of the financial instrument CNS PHARMACEUTICALS INC. regarding all markets in English.

> News GlobeNewsWire published a news.

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM • • GlobeNewsWire • Stocks

LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP) , a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands...

Thank you Chart

> News GlobeNewsWire published a news.

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme • • GlobeNewsWire • Stocks

LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of...

Thank you Chart

> News GlobeNewsWire published a news.

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application • • GlobeNewsWire • Stocks

HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc . (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication...

Thank you Chart

> News GlobeNewsWire published a news.

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy • • GlobeNewsWire • Stocks

HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication...

Thank you Chart

> News GlobeNewsWire published a news.

CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin • • GlobeNewsWire • Stocks

HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced it has selected Image Analysis Group (“IAG”) as the image partner for its upcoming Berubicin clinical trials. IAG, a leading medical imaging company, will work closely with CNS during the Berubicin...

Thank you Chart

> News GlobeNewsWire published a news.

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones • • GlobeNewsWire • Stocks

Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company’s lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a...

Thank you Chart